NRAS and cancer: Most of the cancers with KRAS, NRAS, or BRAF activating mutations in the absence of a TP53 mutation were subsequently found to be non-HGOC, and the lack of response to rucaparib in these cancers indicates the importance of confirming histological subtype when these mutations are detected.